 Samuel Ellis
Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 12 | 2024 | 3793 | 0.840 |
Why?
| | Blood Glucose | 8 | 2024 | 2286 | 0.750 |
Why?
| | Hypoglycemic Agents | 7 | 2024 | 1380 | 0.610 |
Why?
| | Hypoglycemia | 7 | 2024 | 470 | 0.580 |
Why?
| | Monitoring, Ambulatory | 2 | 2008 | 90 | 0.520 |
Why?
| | Insulin | 4 | 2014 | 2472 | 0.380 |
Why?
| | Diabetes Mellitus | 6 | 2012 | 1078 | 0.350 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2011 | 48 | 0.340 |
Why?
| | Comorbidity | 2 | 2015 | 1671 | 0.340 |
Why?
| | Pyrazines | 1 | 2011 | 88 | 0.330 |
Why?
| | Administration, Inhalation | 2 | 2014 | 594 | 0.330 |
Why?
| | Triazoles | 1 | 2011 | 163 | 0.320 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2016 | 2529 | 0.320 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2024 | 713 | 0.280 |
Why?
| | Pharmacists | 2 | 2000 | 256 | 0.270 |
Why?
| | Insulin Resistance | 1 | 2015 | 1221 | 0.250 |
Why?
| | Dried Blood Spot Testing | 2 | 2024 | 125 | 0.230 |
Why?
| | Drug Monitoring | 2 | 2024 | 396 | 0.200 |
Why?
| | Emtricitabine | 1 | 2024 | 204 | 0.200 |
Why?
| | Ventricular Remodeling | 1 | 2025 | 258 | 0.190 |
Why?
| | Diabetic Nephropathies | 2 | 2018 | 293 | 0.190 |
Why?
| | Adenine | 1 | 2024 | 335 | 0.180 |
Why?
| | Obesity | 1 | 2015 | 3007 | 0.180 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2025 | 338 | 0.180 |
Why?
| | Ventricular Function, Left | 1 | 2025 | 513 | 0.180 |
Why?
| | Heart Rate | 1 | 2025 | 835 | 0.170 |
Why?
| | Community Pharmacy Services | 2 | 2012 | 47 | 0.160 |
Why?
| | Hypolipidemic Agents | 1 | 2000 | 93 | 0.160 |
Why?
| | Bell Palsy | 1 | 1999 | 9 | 0.160 |
Why?
| | Hyperlipidemias | 1 | 2000 | 126 | 0.160 |
Why?
| | Pharmacy Service, Hospital | 1 | 2000 | 83 | 0.160 |
Why?
| | Students, Pharmacy | 2 | 2012 | 101 | 0.150 |
Why?
| | Rural Health Services | 2 | 2012 | 140 | 0.150 |
Why?
| | Treatment Refusal | 1 | 1999 | 96 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 45 | 0.140 |
Why?
| | Anti-HIV Agents | 1 | 2024 | 853 | 0.130 |
Why?
| | Uric Acid | 1 | 2018 | 163 | 0.130 |
Why?
| | Counseling | 1 | 2000 | 395 | 0.130 |
Why?
| | Equipment Design | 2 | 2008 | 528 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2000 | 592 | 0.120 |
Why?
| | Humans | 26 | 2025 | 141284 | 0.120 |
Why?
| | Warfarin | 2 | 2007 | 168 | 0.110 |
Why?
| | Iohexol | 1 | 2014 | 22 | 0.110 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 755 | 0.110 |
Why?
| | Kidney Function Tests | 1 | 2014 | 159 | 0.100 |
Why?
| | Double-Blind Method | 2 | 2025 | 1992 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2018 | 572 | 0.100 |
Why?
| | Cough | 1 | 2014 | 133 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 483 | 0.100 |
Why?
| | Pilot Projects | 3 | 2018 | 1820 | 0.100 |
Why?
| | Software | 2 | 2008 | 675 | 0.100 |
Why?
| | Sitagliptin Phosphate | 1 | 2011 | 33 | 0.090 |
Why?
| | Problem-Based Learning | 1 | 2012 | 96 | 0.090 |
Why?
| | Female | 15 | 2025 | 75814 | 0.080 |
Why?
| | Anticoagulants | 2 | 2007 | 724 | 0.080 |
Why?
| | Postprandial Period | 1 | 2011 | 111 | 0.080 |
Why?
| | Hypertension | 1 | 1999 | 1250 | 0.080 |
Why?
| | Male | 14 | 2025 | 70140 | 0.080 |
Why?
| | Education, Pharmacy | 1 | 2012 | 126 | 0.080 |
Why?
| | Plant Preparations | 1 | 2010 | 37 | 0.080 |
Why?
| | Adult | 10 | 2024 | 39319 | 0.080 |
Why?
| | Middle Aged | 9 | 2025 | 34658 | 0.080 |
Why?
| | Ambulatory Care Facilities | 1 | 2012 | 245 | 0.080 |
Why?
| | Nonprescription Drugs | 1 | 2010 | 65 | 0.080 |
Why?
| | HIV Infections | 1 | 2024 | 2981 | 0.080 |
Why?
| | Health Planning Guidelines | 1 | 2009 | 24 | 0.080 |
Why?
| | Hospitals, Veterans | 2 | 2000 | 255 | 0.070 |
Why?
| | Cross-Over Studies | 1 | 2011 | 578 | 0.070 |
Why?
| | Comparative Effectiveness Research | 1 | 2010 | 163 | 0.070 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 189 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1105 | 0.070 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 74 | 0.070 |
Why?
| | Physician's Role | 1 | 2009 | 218 | 0.070 |
Why?
| | Dental Care for Chronically Ill | 1 | 2007 | 10 | 0.070 |
Why?
| | Faculty, Dental | 1 | 2007 | 8 | 0.070 |
Why?
| | Nebulizers and Vaporizers | 1 | 2007 | 68 | 0.060 |
Why?
| | Long-Term Care | 1 | 2007 | 110 | 0.060 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2007 | 99 | 0.060 |
Why?
| | Biosensing Techniques | 1 | 2008 | 138 | 0.060 |
Why?
| | Patient Care Team | 1 | 2012 | 667 | 0.060 |
Why?
| | Education, Dental | 1 | 2007 | 35 | 0.060 |
Why?
| | Forecasting | 1 | 2007 | 383 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2904 | 0.060 |
Why?
| | Self Care | 1 | 2008 | 387 | 0.060 |
Why?
| | United States | 4 | 2011 | 15298 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 35 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2091 | 0.050 |
Why?
| | Hyperglycemia | 1 | 2008 | 365 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 144 | 0.050 |
Why?
| | Prevalence | 2 | 2008 | 2795 | 0.050 |
Why?
| | Alanine | 1 | 2024 | 159 | 0.050 |
Why?
| | Coronary Disease | 1 | 2006 | 373 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2025 | 227 | 0.050 |
Why?
| | Diabetes Complications | 3 | 2014 | 222 | 0.050 |
Why?
| | Homeostasis | 1 | 2007 | 632 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 178 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 157 | 0.050 |
Why?
| | Benchmarking | 1 | 2024 | 179 | 0.050 |
Why?
| | Muscle Proteins | 1 | 2025 | 235 | 0.050 |
Why?
| | Activities of Daily Living | 1 | 2007 | 429 | 0.050 |
Why?
| | Circadian Rhythm | 1 | 2007 | 509 | 0.050 |
Why?
| | Data Collection | 2 | 2010 | 655 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 1973 | 0.050 |
Why?
| | Tenofovir | 1 | 2024 | 288 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 598 | 0.050 |
Why?
| | Patient Education as Topic | 2 | 2012 | 771 | 0.040 |
Why?
| | Health Status | 1 | 2007 | 822 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2025 | 11216 | 0.040 |
Why?
| | Lipoproteins, LDL | 1 | 2000 | 112 | 0.040 |
Why?
| | Atrial Fibrillation | 1 | 2006 | 501 | 0.040 |
Why?
| | Facial Nerve | 1 | 1999 | 39 | 0.040 |
Why?
| | Aged | 4 | 2025 | 24836 | 0.040 |
Why?
| | Pharmaceutical Services | 1 | 2000 | 83 | 0.040 |
Why?
| | Risk Factors | 3 | 2006 | 10490 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 2000 | 374 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 166 | 0.030 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 612 | 0.030 |
Why?
| | Depression | 1 | 2007 | 1490 | 0.030 |
Why?
| | Stroke | 1 | 2006 | 1199 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 550 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2929 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3172 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 491 | 0.030 |
Why?
| | Prospective Studies | 2 | 2010 | 7805 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 112 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2024 | 16447 | 0.020 |
Why?
| | Organizational Objectives | 1 | 2012 | 65 | 0.020 |
Why?
| | Medically Underserved Area | 1 | 2012 | 99 | 0.020 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 190 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2012 | 1395 | 0.020 |
Why?
| | Professional-Patient Relations | 1 | 2012 | 149 | 0.020 |
Why?
| | Databases, Factual | 2 | 2007 | 1449 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2000 | 5222 | 0.020 |
Why?
| | Computer Communication Networks | 1 | 2010 | 32 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2012 | 456 | 0.020 |
Why?
| | Perception | 1 | 2012 | 375 | 0.020 |
Why?
| | Time Factors | 1 | 2000 | 6951 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 919 | 0.020 |
Why?
| | Adolescent | 3 | 2014 | 22116 | 0.020 |
Why?
| | Fluoroquinolones | 1 | 2007 | 43 | 0.020 |
Why?
| | National Health Programs | 1 | 2006 | 20 | 0.020 |
Why?
| | International Normalized Ratio | 1 | 2006 | 50 | 0.010 |
Why?
| | Income | 1 | 2007 | 198 | 0.010 |
Why?
| | Monte Carlo Method | 1 | 2006 | 150 | 0.010 |
Why?
| | Models, Economic | 1 | 2006 | 61 | 0.010 |
Why?
| | Blood Pressure | 1 | 2012 | 1740 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2047 | 0.010 |
Why?
| | Surveys and Questionnaires | 2 | 2007 | 5948 | 0.010 |
Why?
| | Clinical Competence | 1 | 2012 | 1210 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2012 | 1178 | 0.010 |
Why?
| | Bayes Theorem | 1 | 2006 | 414 | 0.010 |
Why?
| | Cognition Disorders | 1 | 2007 | 520 | 0.010 |
Why?
| | Health Care Costs | 1 | 2006 | 417 | 0.010 |
Why?
| | Colorado | 1 | 2012 | 4599 | 0.010 |
Why?
| | Biomarkers | 1 | 2012 | 4180 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1764 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1035 | 0.010 |
Why?
| | Primary Health Care | 1 | 2010 | 1757 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 13727 | 0.010 |
Why?
| | Risk Assessment | 1 | 2006 | 3522 | 0.010 |
Why?
| | Infant | 1 | 2010 | 9820 | 0.010 |
Why?
| | Child, Preschool | 1 | 2010 | 11511 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2007 | 7948 | 0.010 |
Why?
| | Child | 1 | 2010 | 22390 | 0.000 |
Why?
|
|
Ellis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|